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Abstract
Rationale Recent studies have assessed the therapeutic potential of ayahuasca for the treatment of depression with promising
preliminary results.
Objectives Here, we examine the course of grief over 1 year of follow-up in a bereaved sample that attended a center in Peru to
participate in indigenous Shipibo ayahuasca ceremonies. We also explore the roles of experiential avoidance and decentering as
mechanisms of change.
Methods Bereaved participants who attended the ayahuasca center responded to an online survey that included the Texas
Revised Inventory of Grief, Symptom Assessment-45, WHO Quality of Life-Bref, Acceptance and Action Questionnaire, and
Decentering. Baseline assessment was completed by 50 individuals (T0). Of these, 39 completed the post-assessment at 15 days
(T1), 31 at 3 months (T2), 29 at 6 months (T3), and 27 at 12 months (T4) after leaving the retreat. Pearson’s analysis was
performed to examine the relationship between the severity of grief and mechanisms of change during the period of T0 and T1.
Results A significant decrease in Texas Revised Inventory was observed at all time points (T1: Cohen’s d = 0.84; T2: Cohen’s
d = 1.38; T3: Cohen’s d = 1.16; T4: Cohen’s d = 1.39). We found a relationship between experiential avoidance (r = 0.55;
p < .01), decentering (r = − 0.47; p < .01), and a reduction in the severity of grief.
Conclusions Our results suggest that the ceremonial use of ayahuasca has therapeutic value by reducing the severity of grief.
Acceptance and decentering are both psychological processes that mediate the improvement of grief symptoms.
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Introduction
The word “ayahuasca” is derived from the Quechua language,
aya means “dead person, spirit, soul, or ancestor” and huasca
means “rope or vine” (Metzner, 2005). Ayahuasca is a natural
plant concoction used by indigenous groups throughout the
Amazon Basin in traditional medicine and spiritual rituals
(Schultes and Hofmann, 1992). The concoction is usually
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prepared by boiling the stems of the Banisteriopsis caapi vine
with the leaves of the Psychotria viridis shrub, or Diplopterys
cabrerana leaves (Schultes and Hofmann, 1992). B. caapi is
rich in beta-carbolines, which have monoamine oxidase-
inhibiting properties, the main pharmacological mechanism
of some antidepressants currently used in clinical practice
(Meister et al. 2016). P. viridis and D. cabrerana contain the
tryptamine N,N-dimethyltryptamine (DMT) that acts as an
agonist of 5-HT-2A and sigma-1 receptor sites, which is also
associated with antidepressant, anxiolytic, and psychoactive
effects (Fontanilla et al. 2009; Domínguez-Clavé et al. 2016).
The evidentiary literature on ayahuasca’s pharmacological
safety among healthy volunteers (Dos Santos et al. 2013,
2012; Riba et al. 2003), and the lack of dose tolerance and
addictive potential (Fábregas et al. 2010), has triggered exten-
sive scientific research into this concoction during the last two
decades. Single-photon emission computed tomography
(SPECT) techniques have shown ayahuasca to produce an
increased blood perfusion in the left nucleus accumbens, right
insula and left subgenual area, brain regions implicated in the
regulation of mood and emotions (Sanches et al. 2016).
Functional magnetic resonance imaging have shown a signif-
icant decrease in the activity of the Default Mode Network
(DMN) (Palanho-Fontes et al. 2015), a brain network that is
hypperactivated in patients with major depressive disorder
(MDD), which is associated with maladaptive rumination
and self-referential processes (Hamilton et al. 2011; Sheline
et al. 2009). Moreover, ayahuasca enhances creative divergent
thinking, a psychological process underlying psychological
flexibility that is relevant to the success of cognitive therapy
(Kuypers et al. 2016). Regular ayahuasca ceremony partici-
pants have performed well on neuropsychological tests
(Bouso et al. 2012, 2015) and show low levels of psychopath-
ological symptoms (Bouso et al. 2012, 2015; Barbosa et al.
2009). Rapid anxiolytic and antidepressant effects have been
demonstrated in animals (Da Silva et al. 2018; Cameron et al.
2018) and human beings (Dos Santos et al. 2007; Palhano-
Fontes et al. 2019; Osorio et al. 2015). A recent study
supporting these results observed a modulation of salivary
cortisol in major depression treatment-resistant patients,
where concentrations similar to those of healthy volunteers
were reached 48 h after a single dose of ayahuasca (Galvão
et al., 2018).
Studies about the mediating psychological processes un-
derpinning ayahuasca’s therapeutic potential are also growing.
A previous study found that 4 ayahuasca sessions could be as
effective at reducing experiential avoidance (or, formulated
positively, at promoting the acceptance of negative feelings
and thoughts) as 8 weeks of mindfulness-based stress reduc-
tion (MBSR) (Soler et al. 2018). Decentering, defined as the
ability to observe one’s thoughts and feelings in a detached
manner (Fresco et al. 2007), also improves 24 h after drinking
ayahuasca (Soler et al. 2016). This ability seems to increase
even more in people who drink ayahuasca regularly
(Franquesa et al. 2018), as long as they do not possess border-
line personality traits (Domínguez-Clavé et al., 2019). Other
studies have found improvements in other mechanisms of
change that are also classic goals of mindfulness training.
This is the case for positive self (Franquesa et al. 2018), inner
reactivity, and the judgmental processing of experiences
(Soler et al. 2016).
Until now, only one exploratory observational study has
found preliminary evidence regarding the therapeutic poten-
tial of ayahuasca for grief related to the death of a loved one
(González et al. 2017). Bereavement, defined as the period of
grief and mourning after the death of a love one, is a universal
condition and one of the most painful experiences that humans
face. Feeling stunned or shocked, emotional numbness, mis-
trust of others, bitterness over the loss, confusion about one’s
role in life, a diminished sense of self, difficulty accepting the
loss, and moving on with life are normal reactions when be-
reaved in the aftermath of a death of a love one (Prigerson
et al. 2009). Prolonged Grief Disorder (PGD) has recently
been included in the latest version of the International
Classification of Disease (ICD-11) (World Health
Organization, 2018), with an estimated prevalence of 9.8%
among bereaved individuals (Lundorff et al. 2017). Core
PGD symptoms include pervasive yearning for the deceased
and persistent preoccupation with the deceased, accompanied
by intense emotional pain for, at minimum, 6 months post-
loss. In addition, PGD is characterized by cognitive, emotion-
al, and behavioral symptoms that disrupt the individual’s abil-
ity to function in different contexts (World Health
Organization, 2018). Research has found that symptoms of
PGD are associated with impairment of the bereaved person’s
familiar, social and occupational functioning to a similar ex-
tent as found in depression and post-traumatic stress disorder
(Prigerson et al. 2009; Jordan and Litz 2014; Maercker et al.
2013). Drugs alone have not been shown to effectively treat
PGD symptoms (Zisook and Shear 2009; Shear et al. 2016).
The latest meta-analysis of controlled trials found that the
mean effect sizes of the current psychotherapeutic interven-
tions are smaller than those of treatments for other psychiatric
disorders (Johannsen et al. 2019; Wittouck et al. 2011).
Moreover, the results from grief interventions on non-
pathological grief provide inconsistent support for their effec-
tiveness (Wittouck et al. 2011).
The present study investigated the long-term effects of aya-
huasca in participants who are grieving the death of a loved
one, following a sample of subjects with a history of grief who
willingly attended ayahuasca ceremonies at an ayahuasca cen-
ter in Peru. The primary outcome variable was the severity of
grief. Secondary variables were psychopathological symp-
toms, quality of life, experiential avoidance, and decentering.
We hypothezised that the severity of grief would be reduced
after drinking ayahuasca at the center. Second, we
1172 Psychopharmacology (2020) 237:1171–1182
hypothezised that psychopathological symptoms, quality of
life, and both psychological processes would also improve
after drinking ayahuasca. Given that previous studies have
shown that acceptance and decentering are psychological pro-
cesses underlying ayahuasca’s effects, and given that both
constructions play an important protective role in psychopa-
thology models, we finally hypothesized that the improve-
ment of both psychological processes would mediate the re-
duction in the severity of grief.
Methods
This study is part of a broader study that aims to prospectively
assess the long-term effects of ayahuasca on well-being and
quality of life, as well as psychopathological symptoms in
different subsamples with depression, anxiety, post-traumatic
stress disorder, and grief (data are currently pending publica-
tion). In the present article, only the data for the grief subsam-
ple has been included and analyzed.
Participants and procedure
Participant enrollment was carried out between 2015 and
2017. During 2018, the follow-up period of 1 year was con-
cluded. Participants were invited to participate in the study
through the website of the Temple of the Way of Light
(Temple of the Way of Light 2016), after having booked their
stay at the center. This center offered retreats of 9, 12, or
30 days, where participants drank ayahuasca between 4 and
9 times in a ceremonial context under the guidance of Shipibo
Curanderos (traditional healers). The retreat also offers option-
al yoga classes, floral and steam baths, and integration circles
concerning ayahuasca experiences. Information about the re-
treats is available online (Temple of the Way of Light 2016).
Despite the fact that these programs were not specifically de-
veloped to treat grief symptoms, our goal was to reach a suf-
ficient number of participants who were suffering from the
loss of a loved one when they attended the retreat.
A total of 50 participants were elegible for the analysis. The
screening process involved two stages. First, to be accepted by
the center, which requires individuals to be 18 years of age or
older. People with previous clinical disorders (i.e., psychosis,
depersonalization, or mania), people who were taking certain
medications (i.e., MAOIs or SSRIs), people with a heart con-
dition, those with chronic high blood pressure, and pregnant
women were not accepted (Temple of theWay of Light 2019).
Second, to respond to a short online questionnaire including
the following questions: (a) Please indicate the exact date
when you will attend to the retreat; (b) please mark “yes,”
“uncertain,” or “no” to the following questions: are you cur-
rently going through a period of (b.1) depression; (b.2) anxi-
ety; (b.3) post-traumatic stress; (b.4) grief related to the death
of a loved one; (c) can you understand with ease everything
you read in the English language? Participants were included
in the study if they affirmed feeling grief symptoms related to
the death of a loved one (regardless of whether they claim to
be going through a period of depression, anxiety, or trauma)
and they affirmed having an adequate knowledge of the
English language.
Once participants were included in the study, assessments
were done 15 days before attending the retreat (T0) and
15 days (T1), 3 months (T2), 6 months (T3), and 12 months
(T4) after leaving the retreat. Participants who were included
in the study more than 2 months before attending the center
were invited to respond to an additional assessment 2 months
before entering the center (T-1) in order to control for the
effect of time on outcomes in a subgroup.
All questionnaires were administered online using
LimeSurvey (version 1.92.), which allowed for the collection
and preservation of the data on a secure server that is accessi-
ble only to the researchers via a password.
Measures
Texas Revised Inventory of Grief This questionnaire is a self-
report measure designed to quantify the severity of grief
(Faschingbauer 1981). In this study, only the Present
Feelings Scale was used to measure a person’s emotional state
at the time of the questionnaire’s completion. The question-
naire comprises a total of 13 items scored on a 5-point Likert-
type scale (1 = completely false to 5 = completely true). The
Texas Revised Inventory of Grief (TRIG) is score by calculat-
ing the average scores for the subscale. Higher scores indicate
a greater severity of grief. The scale has been shown to have
adequate psychometric properties with Cronbach’s coefficient
alpha value of .90 in the present feelings scale.
Symptom Assessment-45 Questionnaire This questionnaire is
a self-report clinical measure designed to assess psychiatric
symptoms in 9 different symptom domains, as well as to pro-
vide a general measure of overall psychiatric distress (GSI)
(Davison et al., 1997). It contains 45 items, which fall into the
following scales: Anxiety, Hostility, Obsessive-Compulsive,
Phobic Anxiety, Somatization, Depression, Interpersonal
Sensitivity, Paranoid Ideation and Psychoticism. Examinees
are asked to indicate how much the particular problem has
bothered them during the past 7 days on a 5-point Likert-type
scale (0 = not at all to 4 = extremely). The Symptom
Assessment-45 Questionnaire (SA-45) has been normed using
both non-patient (N = 1621) and clinical samples (N = 13.844)
(Maruish et al. 1998). Each of the samples included norms for
both adolescent and adult males and females. Raw scores are
transformed into standard T scores (M = 50, SD = 10). The
scale has been shown to have adequate psychometric
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properties with Cronbach’s coefficient alpha values ranging
from 0.69 to 0.92.
World Health Organization Quality of Life-BREFThis question-
naire is a shorter version of the original WHOQOL-100
(Whoqol Group 1998). This questionnaire was designed to
assess quality of life in four domains: Physical Health,
Psychological Health, Social Relat ionships, and
Environment. For the purpose of this study, only the first three
scales were used. The questionnaire comprises a total of 24
items, scored on a 4–20 scale, with higher scores indicating a
better quality of life. The scale has been shown to have ade-
quate psychometric properties with Cronbach’s coefficient al-
pha values ranging from 0.68 to 0.82 (Skevington et al. 2004).
Acceptance and Action Questionnaire This is a unidimension-
al scale that assesses the construct referred to variously as
experiential avoidance or, when it is positively formulated,
acceptance (Bond et al. 2011). Experiential avoidance refers
to avoidance of the experience of internal events, such as
attempts to suppress or control emotions (Hayes 1987).
Participants indicate their response to each question using a
7-point Likert-type scale (1 = never true to 7 = always true).
The Acceptance and Action Questionnaire (AAQ-II) is score
by adding together all the items, with higher scores corre-
sponding to greater experiential avoidance. This questionnaire
has been shown to have adequate psychometric properties
with a Cronbach’s coefficient alpha value of 0.82.
EQ-Decenetering This scale assesses decentering, defined as
the ability to observe one’s thoughts and feelings in a detached
manner (Fresco et al. 2007). The original scale was called the
Experiences Questionnaire (EQ), in which participants rate
items on a 7-point Likert-type scale (1 = never to 7 = all the
time), assessing decentering and rumination (Fresco et al.
2007). Based on the psychometric characteristics of the orig-
inal scale, which showed poor loadings for other items placed
on the rumination factor and a robust structure for the
decentering factor, only the EQ-Decentering scale was used
for the present study. This is an 11-item self-report measure of
decentering. Items are rated on a 5-point Likert scale (1 =
never to 5 = always). The original EQ showed a high reliabil-
ity coefficient with Cronbach’s alpha value of 0.90.
Bereavement adjustment questionnaire An additional ques-
tionnaire was designed to explore bereavement adjustment
during follow-up assessments (Appendix 1). These questions
covered the following: participants’ subjective perceptions
about the evolution of their clinical status; the persistent
long-term harms and benefits derived from ayahuasca intake
during their stay at the center; and participants’ use of ayahua-
sca, medication and psychotherapy to treat grief symptoms
after leaving the center (at T1, T2, T3, and T4).
Ayahuasca samples analyses
We obtained samples of two different ayahuasca batches
prepared by Shipibo shamans at the Temple of the Way of
Light along the period of the study. The ayahuasca was
prepared by boiling the stems of B. caapi (rich in
harmine, tetrahydroharmine, and harmaline) combined
with the leaves of P. viridis (rich in N,N-dimethyl-trypt-
amine) for several hours. Analyses were carried out by
Energy Control (energycontrol-international.org) using
liquid chromatography-mass spectrometry (LC-MS). One
ayahuasca sample contained 2 mg/ml N, N-DMT,
2 mg/ml of harmine, 0.37 mg/ml of harmaline, and
1 mg/ml of tetrahydroharmine. The other sample
contained 2 mg/ml N, N-DMT, 2 mg/ml of harmine, 0.
6 5 m g / m l o f h a r m a l i n e , a n d 2 m g / m l o f
tetrahydroharmine. No other psychoactive compounds
were detected.
Statistical analysis
Baseline sample characteristics, setting variables, and be-
reavement adjustment over time were analyzed descrip-
tively. Changes in primary and secondary outcome vari-
ables between each time point and baseline were tested
using Student’s paired two-sided t test or the Wilcoxon
paired test, as appropriate. Bonferroni corrections were
applied to correct for multiple comparisons. A 95% CI
for the mean of the primary outcome at all time point
assessments was included to further clarify plausible
values. Effect sizes were calculated using Cohen’s d.
Effect sizes were defined as large up to 0.8 (d > 0.8)
(Cohen 1988). To examine the relationship between expe-
riential avoidance (AAQ-II), decentering (EQ-D), and the
severity of grief (TRIG), we used Pearson’s linear corre-
lation coefficient. Correlation coefficients between 0.30
and 0.70 were considered moderate.
Additional subgroup analysis was performed separate-
ly for patients who responded to T-1, T0, and T1 as-
sessments. We used the chi-square test for categorical
variables and Fisher-Snedecor for continuous variables
to evaluate homogeneity between the group who com-
pleted the follow-up at T1, and a subgroup that com-
pleted an additional assessment at T-1. Subgroup analy-
ses were conducted using repeated measures analysis of
variance (ANOVAs) with post hoc Bonferroni-correc-
tion, in order to examine differences in primary and
secondary outcomes between the periods of T-1 to T0
and T1 to T0.
In this study, p values < 0.05 were considered statisti-
cally significant. Statistical analysis was performed using
Statistical Package for the Social Sciences (SPSS for
Windows, version 20).
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Results
Participants
Out of 117 participants who were assessed for eligibility,
79.49% participants signed the informed consent form.
However, 30.1% participants were excluded because baseline
data were not available, 12.91% were excluded because no
follow-ups were available, and 3.23% expressed a desire to
abandon the study. Finally, 50 participants were elegible for
the analysis, having completed the baseline assessment and, at
least, one follow-up assessment. Overall, the rate of partici-
pants not responding to the assessment at T1 was 22%, at T2,
it was 38%, at T3, it was 42%, and 46% at T4 (Fig. 1).
Baseline sample characteristics
Demographic and bereavement characteristics of participants
are summarized in Table 1.
The quality of the relationship with the deceased was pos-
itive for 68%, negative for 12%, and ambiguous for 20%. For
82% of participants, the death was considered a traumatic
event and 14% were unsure. Among the sample, 68% had lost
an average of 4.11 (SD = 2.15) significant people in the past
(range 2–10).
The main motivations for attending the retreat were thera-
peutic (34.1%), spiritual growth (34.1%), and personal devel-
opment (31.7%). None of the participants affirmed a recrea-
tional purpose, such as drug tourism. Among the sample, 76%
expected that the ayahuasca ceremonies at the center would
improve their grief symptoms and 24% were not sure. Of the
overall sample, 70% had never used ayahuasca before. Of the
remaining 30% of the sample (n = 15), 40% drank ayahuasca
less than 3 times, 40% between 3 and 7 times, and 20% more
than 7 times.
Setting variables
Participants attended an average of 18.1 (SD = 8.7) days at the
center (range 9–30), where they participated in an average of
6.62 (SD = 1.37) ayahuasca ceremonies (range 4–9). Of the 39
participants who responded at T1, 53.8% perceived ayahuasca
as the most relevant factor in the evolution of their grief symp-
toms during their stay at the center, followed by the work of
the Shipibo healers (35.9%), being with other guests (5.1%),
the experience of being in the jungle (2.6%), and having
attended other alternative activities, such as yoga classes
(2.6%). Moreover, 78.4% described an ayahuasca experience
that directly affected their grief process.
Main outcome analyses
The results for outcome variables at all assessment points (T0,
T1, T2, T3, and T4) are presented in Table 2.Fig. 1 Participant flow throughout the study
Table 1 Demographic and bereavement characteristics of participants
Characteristics Total Sample (n = 50)
n %
Female 33 66






University education 39 78
Employed 36 72
Active member of a religious organization 3 6
Caucasian 38 77.6
First-degree relationship to deceased 39 78
Unnatural death (suicide, homicide, accident) 19 38
Years since loss
0 to 3 years 11 22.9
4 to 7 years 19 39.6
8 to 15 years 9 18.8
More than 15 years 9 18.8
Previous therapy for grief 27 54
Previous medication for grief 14 28
Previous ayahuasca for grief 10 20
*Data are expressed as mean (SD) [range]
Psychopharmacology (2020) 237:1171–1182 1175
TRIG score was significantly reduced from baseline to all
point times follow-up assessment (T1, T2, T3, and T4:
p < 0.001). This significant improvement in the severity of
grief is shown graphically with confidence intervals (95%
CI) (Fig. 2). Calculating effect sizes according to Cohen’s
method, we found a high effect size at all assessments points
(T1 = 0.84, 95% CI = 0.45–1.23; T2 = 1.38, 95% CI = 0.92–
1.80; T3 = 1.16, 95% CI = 0.72–1.64; and T4 = 1.39, 95%
CI = 0.93–1.88).
Similarly, SA-45 showed a significant improvement on the
Global Severity Index (GSI) for all assessments (T1, T2, T3,
and T4: p < 0.001), showing a high effect size at T1 = 1.11,
95% CI = 0.77–1.45; T2 = 1.06, 95% CI = 0.73–1.39; T3 =
0.90, 95% CI = 0.59–1.22; and T4 = 1.1, 95% CI = 0.68–
1.52. Almost all of the psychopathological subscales of SA-
45 showed a significant decrease after the retreat (T1: p ≤
0.003), which were maintained over the follow-up assess-
ments (T2: p ≤ 0.018; T3: p ≤ 0.017; and T4: p ≤ 0.005) with
the exception of hostility at T3 (p = 0.451) and T4 (p = 0.087).
The only subscale that did not show a significant decrease
after the retreat was phobic anxiety (T1: p = 0.062), although





















TRIG 40.5 (9.6) 31.1 (9.3)*** 29.7 (9.8)*** 31.8 (8.9)*** 29.7 (9.1)***
SA-45
Hostility 59.0 (5.6) 55.2 (4.1)*** 55.9 (4.3)* 57.4 (5.5) 56.8 (4.6)
Somatization 62.3 (9.3) 57.5 (6.6)*** 56.0 (8.3)*** 56.9 (7.9)** 57.9 (9.0)***
Depression 62.0 (6.9) 55.3 (8.5)*** 56.0 (6.8)** 57.0 (6.3)* 57.0 (9.0)**
Obsess. compulsive 63.9 (8.5) 56.9 (7.4)*** 56.4 (8.0)*** 57.1 (7.8)*** 58.1 (9.2)**
Anxiety 63.9 (8.5) 54.1 (6.8)*** 55.7(7.2)*** 56.4 (8.1)** 55.7 (9.7)***
Interp. sensitivity 62.7 (6.7) 55.5 (6.5)*** 56.3 (6.4)*** 55.8 (7.0)*** 55.6 (6.4)***
Phobic anxiety 65.3 (6.4) 63.1 (5.6) 61.6 (4.7)** 61.8 (4.3)* 60.9 (4.9)***
Paranoid ideation 59.0 (7.7) 53.0 (6.7)*** 53.2 (6.8)*** 54.8 (7.5)* 54.1 (7.9)**
Psychoticism 63.4 (5.3) 60.5 (3.6)** 59.9 (3.4)*** 60.0 (3.2)** 60.2 (3.5)***
GSI 63.2 (7.7) 54.2 (7.9)*** 53.7 (8.9)*** 54.8 (8.8)*** 55.1 (9.0)***
WHOQoL
Physical health 14.7 (2.9) 16.5 (2.8)*** 17.0 (2.2)*** 16.6 (2.2)*** 16.2 (2.6)**
Psychological health 12.6 (2.9) 15.6 (2.4)*** 15.5 (2.2)*** 15.6 (1.5)*** 14.7 (2.5)**
Social relationships 12.3 (3.2) 15.0 (3.9)*** 14.8 (3.1)** 15.4 (3.1)** 14.1 (3.6)**
AAQ-II 27.0 (7.0) 18.8 (5.7)*** 18.7 (5.7)*** 19.4 (5.6)*** 19.4 (6.7)***
EQ-Delefting 35.3 (7.3) 42.5 (6.2)*** 43.3 (5.7)*** 42.6 (4.9)*** 43.3 (6.6)***
†Bonferroni correction is performed
a p value calculated by paired sample t test from T0 to T1 (N = 39)
b p value calculated by paired sample t test from T0 to T2 (N = 31)
c p value calculated by paired sample t test from T0 to T3 (N = 29)
d p value calculated by paired sample t test from T0 to T4 (N = 27)
Asterisks indicate p values: *p < .05; **p < .01; ***p < .001 in the paired sample t tests
Fig. 2 Graph of the mean values (dots) and confident intervals (CI, 95%)
of the severity of grief at baseline (T0) and follow-up (T1, T2, T3, and T4)
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a significant reduction in this symptom was observed over
subsequent assessments (T2: p = 0.002; T3: p = 0.016; and
T4: p < 0.001).
Finally, the Symptom Assessment-45 Questionnaire
(WHOQoL-BREF) questionnaire also showed significant
improvements in physical health, psychological health,
and social relationship scales after the retreat (T1:
p < 0.001). The improvements in physical health were
maintained at T2, T3, and T4 (p < 0.001); in psychologi-
cal health at T2, T3, and T4 (p < 0.001); and in social
relationships at T2 (p = 0.003), T3 (p = .001), and T4
(p = 0.004). The effect size was larger for the psycholog-
ical health subscale (T1 = 0.92, 95% CI = 0.056–1.26;
T2 = 0.89, 95% CI = 0.54–1.27; T3 = 0.82, 95% CI =
0.53–1.11; and T4 = 0.73, 95% CI = 0.33–1.08).
Both mechanisms of change, experiential avoidance
(AAQ-II) and decentering (EQ-Decentering), significantly
improved after the retreat (T1: p < 0.001), maintaining
these gains at all follow-up assessments (T2, T3, and
T4: p < 0.001). AAQ-II showed a high effect size for all
assessments, as T1 = 0.90, 95% CI = 0.62–1.18; T2 = 1.09,
95% CI = 0.72–1.48; T3 = 1.14, 95% CI = 0.80–1.51; and
T4 = 1.07, 95% CI = 0.57–1.53. EQ-Decentering also
showed a high effect size for all assessments, as T1 =
0.96, 95% CI = 0.64–1.28; T2 = 0.99, 95% CI = 0.55–
1.43; T3 = 0.93, 95% CI = 0.46–1.36; and T4 = 1.26,
95% CI = 0.86–1.66.
Bereavement adjustment over time
The ayahuasca experiences at the center had a positive effect on
grief symptoms for 92.3% of the sample, for 5.1%, it had no
influence and 2.6% experienced a negative effect on their grief
process. The bereavement adjustment of the participants at all
follow-up assessments, the uses of therapeutic resources to treat
grief, and the persistent benefits and adverse effects derived from
the ayahuasca experiences at the center are shown in Table 3.
Correlation analysis between grief and mechanism
of change
The significant decrease in experiential avoidance (AAQ-II)
between T0 and T1 was found to be associated with the sig-
nificant decrease in the severity of grief (TRIG) between T0
and T1 (r = 0.55; p < 0.01). In addition, the correlation be-
tween the significant improvement in decentering ability
(EQ-Decentering) between T0 and T1 and the decrease in
grief symptomatology (TRIG) between T0 and T1 (r =
−0.47) was also significant (p < 0.01) (Fig. 3).
Subgroup analysis
Of the 39 participants who completed the follow-up as-
sessment at T1, a subgroup of 9 participants who com-
pleted an additional assessment 2 months prior to the













Perception in relation to grief
I feel worse 1 2.6 0 0.0 0 0.0 1 3.7
I feel the same 2 5.1 2 6.5 1 3.4 0 0.0
I feel better 36 92.3 29 93.5 28 96.6 26 96.3
Persistent adverse effects of ayahuascaa
Physical health 0 0.0 0 0.0 0 0.0 0 0.0
Mental health 0 0.0 0 0.0 0 0.0 1 3.7
Social relationships 1 2.6 1 3.2 0 0.0 1 3.7
Spirituality 0 0.0 0 0.0 0 0.0 1 3.7
Persistent benefits of ayahuascaa
Physical health 30 76.9 19 61.3 18 62.1 17 63.0
Mental health 34 87.2 26 83.9 24 82.1 24 88.9
Social relationships 26 66.7 17 54.8 19 65.5 18 66.7
Spirituality 33 84.6 26 83.9 26 89.7 24 88.9
Therapy to treat grief 4 12.9 8 27.6 9 33.3
Medication to treat grief 0 0.0 0 0.0 1 3.7
Ayahuasca to treat grief 3 9.7 4 13.8 4 14.8
aMultiple choice responses
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retreat (T-1) were elegible for the subgroup analysis
(ANOVA). The homogeneity of the groups was tested
by comparing key variables (baseline characteristics, pri-
mary and secondary outcome measures). No significant
differences were found in baseline sample characteristics
nor outcome variables (p > 0.05). The average number of
days registered in the subsample between T-1 and T0
was 45.0 (SD = 3.87), and between T0 and T1, it was
47.67 (SD = 8.38). ANOVA revealed a significant main
effect of time on the TRIG [F (2; 16) = 11.18, p = 0.001].
Post hoc tests showed a significant improvement only
between T1 and T0 [− 13.26 (SD = 11.17); p = 0.022]
and not between T0 and T-1 [− 1.07 (SD = 5.24);
p > 0.999], indicating that the reduction in the severity
of grief was only observed during participants’ stays at
the center.
Similarly, ANOVA revealed a significant main effect
of time on secondary variables during participants’ stays
at the center. This is the case with the GSI of the SA-45
questionnaire [F (1,4: 10,9) = 10.30; p = 0.006], only be-
tween T1 and T0 [− 8.78 (SD = 7.74); p = 0.028] and not
between T0 and T-1 [0.33 (SD = 3.08); p > 0.999], and
with psychological health of the WHOQol-BREF (F
(1,2; 9,8) =12.28; p = 0.004), only between T1 and T0
[2.52 (1.97); p = 0.015] and not between T0 and T-1
[0.03 (2.33); p > 0.999].
Finally, AAQ-II also showed a significant main effect of
time [F (2,14) = 7.45; p = 0.006], only between T1 and T0 [−
9.88 (SD = 8.59); p = 0.042] and not between T0 and T-1 [3.25
(SD = 4.74); p = 0.281], as well as EQ-Decentering [F
(1,4:10,8) = 7.30; p = 0.015], only between T1 and T0 [7.30
(SD = 6.29); p = 0.025] and not between T0 and T-1 [− 1.47
(SD = 3.25); p = 0.638].
Discussion
This is the first study to prospectively assess the long-term
effects of ayahuasca in participants grieving the death of a
loved one. In this observational study, the primary result
showed that the severity of grief significantly decreased after
drinking ayahuasca, being maintained over 1 year of follow-
up. The subgroup analysis performed in a representative sub-
sample allowed us to infer that the significant differences in
outcomes are due to the effect of their stay at the center and not
the passing of time. The large effect size obtained at all point
assessments on the primary scale clearly exceeds the mean
effect size post-intervention (Hedges’s g = 0.41) and at
follow-up (g = 0.45) obtained in the last meta-analysis focused
on the effectiveness of current treatments developed to treat
complicated grief and prolonged grief disorder (PGD)
(Johannsen et al. 2019). Studies that have obtained higher
effects sizes have applied specific protocols of intervention,
which involved conducting from 12 to 25 psychotherapeutic
sessions during periods of 3 to 9 months, or even longer
(Bryant et al., 2014; Rosner et al. 2014; Boelen et al. 2007).
We dutifully note that the Temple of the Way of Light is not
conducting a specific program to treat grief symptoms, and
that the maximum duration of the retreat was 1 month, during
which ayahuasca was taken a maximum of 9 times.
It is well known that grief symptoms usually present a high
rate of comorbidity with mood and anxiety disorders,
influencing the quality of life of bereaved adults (Boelen and
Prigerson 2007). In our sample, almost all the scales in SA-45
were above the score of 60 at baseline (percentile of 84)
(Davison et al. 1997) suggesting likely problems with soma-
tization, depression, obsessive-compulsiveness, anxiety, inter-
personal sensitivity, phobic anxiety, and psychoticism. With
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Fig. 3 Scatter plot of the relationship between the severity of grief (TRIG) and experiential avoidance (AAQ-II) (a) and decentering (EQ-Decentering)
(b)
the exception of phobic anxiety, all of these symptoms de-
creased significantly at all time points over follow-up to a
level that is considered within the normal range in a non-
patient normative sample (Davison et al. 1997). These results
are in line with previous studies that found lower levels of
psychopathology after drinking ayahuasca in first-time aya-
huasca ceremony participants (Barbosa et al. 2009), as well
as in long-term users as compared with control groups (Bouso
et al. 2012; Dos Santos et al. 2016). Given that phobic anxiety
is expressed through symptoms of uneasiness when in open
spaces and crowds, the fact that we did not find significant
differences in this scale after the retreat, but found differences
throughout later follow-up assessments (T2, T3, and T4),
could indicate a need for a period of time to adapt to the city
environment after being in the jungle. However, phobic anx-
iety and psychoticism are on the threshold of being considered
problematic areas, according to the follow-up assessments. As
far as we know, this is the first article to look deeply into these
psychopathological symptoms among a sample of grievers, so
we cannot compare many of these subscales with other stud-
ies. Only one previous study has assessed a few of these psy-
chopathological symptoms after participants received
prolonged grief-specific cognitive-behavioral therapy
(Rosner et al. 2014), an integrative cognitive-behavioral ap-
proach that includes structured exposures and cognitive
restructuring. In this study, there were no differences in terms
of phobic anxiety, somatization, and anxiety when participants
were compared with a waiting list group.
The significant long-term improvements on all the scales of
quality of life in our sample offer a broader picture of the
impact of ayahuasca on the evolution of grief. Previous stud-
ies have found similar results in first-time ayahuasca ceremo-
ny participants (Barbosa et al. 2009), as well as improvement
in psychosocial well-being in regular participants (Bouso et al.
2012; Dos Santos et al. 2016). However, last meta-analysis on
psychological interventions for grief did not find statistically
significant effects on health-related quality of life (Johannsen
et al. 2019).
Although subjective responses about the persistent harms
and benefits of ayahuasca experiences at the retreat support
the overall outcomes, we must bear in mind that a large pro-
portion of the participants expected that ayahuasca ceremonies
would improve their grief symptoms, which could promote
suggestibility and enhance positive outcomes. The fact that
most of them affirmed that ayahuasca had a positive effect in
terms of mental health and spirituality led us to ponder the role
that spiritual coping played in the adjustment of bereavement
in our sample. Previous studies have shown that spirituality
can play a centrally important role in helping individuals adapt
to the loss of a loved one (Wortmann and Park 2008; Hays and
Hendrix 2008).
In our sample, 78.4% of participants described an ayahua-
sca experience that directly affected their grief process.
Although the content analysis of participants’ ayahuasca ex-
periences is pending publication, a previous study described
emotional confrontations with the reality of the death, the
reviewing of biographical memories, and a reencounter with
the deceased, as common ayahuasca experiences among
grievers (González et al. 2017). The pharmacological effects
of ayahuasca have been described extensively (Dos Santos
et al. 2012, 2013; Riba et al. 2001, 2011), including a dose-
dependent curve with a slow onset during the first 45 min, a
peak in the experience at around 90 min, and slow decrease in
the effects from 150 to 250 min. Under the effects of a medi-
um or high dose, the peak of the experience could be similar to
the immersion used in virtual reality exposure therapy
(VRET), which allows individuals to bypass symptoms of
experiential avoidance (Gonçalves et al. 2012). Other studies
have compared acute ayahuasca effects with a controlled ex-
posure to autobiographical material (Domínguez-Clavé et al.
2016). This acute confrontation with difficult memories,
thoughts, and feelings could promote increased acceptance,
leading to psychological modifications that are observable
beyond the time frame of the acute inebriation (Soler et al.
2018). Although this is the only study that has assessed the
modulation of acceptance (or experiential avoidance) after an
ayahuasca experience over the course of 1 year, our results are
in line with other studies that have found an increase in accep-
tance to result from an ayahuasca experience (Domínguez-
Clavé et al. 2016; Soler et al. 2018). Nevertheless, around
150 min after ayahuasca intake, the intensity of the effects
begins to decrease, allowing a healthy distance from the psy-
chological material and leading to a reflective phase
(Kjellgren et al. 2009). During this phase, decentering could
improve (Fresco et al. 2007). Gains in the ability to decenter
are in line with other studies that have found an increase in
decentering abilities following ayahuasca intake (Domínguez-
Clavé et al. 2016; Soler et al. 2016; Sampedro et al. 2017), and
in those with more than 15 ayahuasca experiences compared
with those with non or few experiences (Franquesa et al.
2018). However, contrary to a previous study (Sampedro
et al. 2017), the gains in decentering in our sample persisted
over a year of follow-up.
These results are also in line with previous studies that
show a positive relationship between high levels of acceptance
and high levels of decentering (Hayes et al. 2017). In our
sample, we observe that increased acceptance and decentering
following the retreat have a significant correlation with im-
provements in the severity of grief. Acceptance is considered a
key mechanism of change in complicated grief treatment
(Glickman et al. 2017), a form of cognitive-behavior therapy
with elements of interpersonal psychotherapy and motivation-
al interviewing (Shear et al. 2016). On the other hand,
decentering is a mediator in the metacognitive approach to
treating grief (Wenn et al. 2015), a form of psychotherapy that
uses detached mindfulness to alter dysfunctional thinking
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styles by helping individuals to understand their “thoughts
about thoughts.” Accommodation (new learning) is a psycho-
logical process that has been associated with an ability to
engage with traumatic experiences when it is combined with
more acceptance and decentering (Hayes et al. 2017).
Accommodation provides an opportunity for constructive pro-
cessing and meaning making regarding the experience
(Neimeyer 2019). Moreover, other kinds of experiences, such
as having a reencounter with the deceased (González et al.
2017), could modulate the internal working model of the de-
ceased and the attachment style maintained with him or her
after death. Future studies should explore more potential
mechanisms of change in order to reach a better understanding
of the therapeutic potential of ayahuasca among the bereaved.
The study has some limitations. First, the naturalistic de-
sign of the study does not allow us to isolate the effects of
ayahuasca from the other diverse variables in the setting,
which include the healing work of the Shipibo shamans during
the ayahuasca ceremony. In fact, the separation of the effects
of ayahuasca from the healer’s work is not conceived of within
the Shipibo traditional medicinal framework, in which partic-
ipants drank the ayahuasca. Moreover, without a placebo
group it is not possible to know if ayahuasca was truly respon-
sible for the improvement in grief symptoms, as it is not pos-
sible to draw conclusions about causality. Second, the lack of
scientific evidence on the stability of ayahuasca alkaloids over
time does not guarantee similar concentrations when partici-
pants took ayahuasca in the center and at the time, the samples
were analyzed. Moreover, the lack of knowledge about the
doses used throughout the ceremonies by each participant pre-
vents us from assessing to relate the improvement in the se-
verity of grief in relation with the doses of DMT or
betacarbolinnes ingested. Third, the sample size is relatively
small and there were a large number of participants that did
not complete all the follow-up assessments. This limitation
can be extended to the subgroup analysis, which was conduct-
ed to control for the effect of time passing. Fourth, nine par-
ticipants attended psychotherapy over the year follow-up, four
took ayahuasca again to treat grief symptoms, and one partic-
ipant took medication, so we cannot attribute the maintenance
of the improvement in grief symptoms exclusively to the per-
sistent benefits of the ayahuasca experiences at the retreat.
Fifth, we did not assess Prolonged Grief Disorder or
Persistent Complex Bereavement Disorder, having used self-
report measures rather than clinical interviews. This, along
with the fact that the sample was heterogeneous, in terms of
the causes of loss and the amount of time that had passed since
the loss, makes the extent to which subgroups profited differ-
ently from ayahuasca uncertain. Lastly, we used a direct meth-
od to recruit participants who were willing to participate in
ayahuasca sessions, which may limit the generalizability of
our results to treatment-seeking bereaved people in general
or whose able to respond an online survey. To reach stronger
conclusions, large controlled cohort studies or randomized,
placebo-controlled trials conducted with adequate samples of
participants will provide evidence of causality.
Conclusions
This study offers preliminary findings in support of the long-
term therapeutic potential of ayahuasca for bereavement. A
significant improvement in the severity of grief and the high
effect size maintained over a year follow-up are sufficiently
encouraging to warrant further research. Furthermore, the as-
sessment of experiential avoidance and decentering highlights
the improvement of these mechanisms of change following
drinking ayahuasca and their relation to grief improvement.
Therefore, more research is necessary to better understand
ayahuasca’s therapeutic value in terms of relief from grief
symptoms.
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